Pages that link to "Q34885043"
Jump to navigation
Jump to search
The following pages link to Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis (Q34885043):
Displaying 50 items.
- Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications (Q24646677) (← links)
- Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital (Q24810927) (← links)
- Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR (Q28477900) (← links)
- Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive Treatment (Q28551361) (← links)
- Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages (Q30341876) (← links)
- DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. (Q33220466) (← links)
- Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae (Q33558893) (← links)
- Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect") (Q34045273) (← links)
- Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms (Q34045376) (← links)
- Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus (Q34057324) (← links)
- Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. (Q34108614) (← links)
- tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus (Q34141289) (← links)
- Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children (Q34157657) (← links)
- Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis (Q34405301) (← links)
- Sccmec type II gene is common among clinical isolates of methicillin-resistant Staphylococcus aureus in Jakarta, Indonesia (Q34632750) (← links)
- Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists (Q34910366) (← links)
- Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia (Q35023343) (← links)
- Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure (Q35038242) (← links)
- In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides (Q35083990) (← links)
- Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods (Q35541702) (← links)
- Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States (Q35598902) (← links)
- Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae (Q35607909) (← links)
- Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials (Q35710192) (← links)
- Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus (Q35806369) (← links)
- Current diagnosis and treatment of infective endocarditis (Q35917305) (← links)
- Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. (Q36025384) (← links)
- Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene (Q36158472) (← links)
- Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). (Q36315377) (← links)
- Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains (Q36328966) (← links)
- The pharmacokinetic and pharmacodynamic properties of vancomycin (Q36328971) (← links)
- Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding (Q36422686) (← links)
- Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings (Q36478309) (← links)
- Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus (Q36667211) (← links)
- Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus (Q36670735) (← links)
- The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus (Q36779557) (← links)
- Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections (Q36847287) (← links)
- Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). (Q36898180) (← links)
- Minimum inhibitory concentration of vancomycin to methicillin resistant Staphylococcus aureus isolated from different clinical samples at a tertiary care hospital in Nepal (Q37113323) (← links)
- Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance (Q37263514) (← links)
- Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus. (Q37323867) (← links)
- LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus (Q37598693) (← links)
- Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. (Q37625238) (← links)
- Heteroresistance at the single-cell level: adapting to antibiotic stress through a population-based strategy and growth-controlled interphenotypic coordination (Q37631528) (← links)
- Efflux Pump Overexpression Contributes to Tigecycline Heteroresistance in Salmonella enterica serovar Typhimurium (Q37647640) (← links)
- Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance (Q37717901) (← links)
- Application of genomic technologies to measure and monitor antibiotic resistance in animals (Q39044602) (← links)
- Prevalence of Slow-growth Vancomycin Non-susceptibility In Methicillin-resistant Staphylococcus aureus (Q40085144) (← links)
- The Global Regulon sarA Regulates β-Lactam Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus In Vitro and in Endovascular Infections (Q40569074) (← links)
- Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods (Q41429045) (← links)
- Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus (Q42027484) (← links)